Navigation Links
Quest PharmaTech Acquires Late-Stage Immunotherapeutic Antibody Pipeline
Date:9/30/2009

TSX Venture: QPT

EDMONTON, Sept. 30 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced that it has acquired a pipeline of late-stage immunotherapy product candidates from Paladin Labs Inc. (TSX:PLB) ("Paladin").

The pipeline of product candidates consists of five monoclonal antibodies targeting certain tumor antigens that are presented in a variety of cancers. The first and most advanced of these product candidates is Oregovomab, an anti-CA125 antibody for the treatment of ovarian cancer patients that Quest will evaluate in combination with front-line chemotherapy.

Quest also acquired anti-MUC1, anti-TAG72, anti-PSA and anti-CA19.9 antibodies that could potentially be used for the treatment of breast, lung, stomach, colorectal, pancreas and prostate cancer.

"We believe that these newly acquired immunotherapeutic antibody products have the opportunity to become significantly more effective when combined with chemotherapy, radioimmuno therapy or photodynamic therapy," said Dr. Madi R. Madiyalakan, Chief Executive Officer for Quest. "As one of the original inventors of this technology, I have a deep understanding of the potential of these compounds to become more efficacious treatments for cancer when used as an adjunct in combination with these established therapies. We intend to expeditiously evaluate the potential of the acquired products for conducting a registration trial for one or more combination therapies, which, if successful, could lead directly to one or more applications for regulatory approval."

As part of the transaction, Paladin receives an upfront payment of $37,500 and 1.5 million common shares of Quest, with an additional 1.5 million common shares to be issued to Paladin on or before December 31, 2010. Paladin may also receive an additional 2
'/>"/>

SOURCE Quest PharmaTech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
2. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
3. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
6. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
7. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
8. Sinovac Requests Extension for Annual Shareholders Meeting
9. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
10. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
11. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... CA (PRWEB) November 21, 2014 Why ... that makes Albert Einstein so instantly recognizable? Why have ... physicist, mathematician, astronomer and author Hilton Ratcliffe seeks out ... have nothing at all to do with science. In ... Harbor Publishing , November 21, 2014), Ratcliffe puts it ...
(Date:11/21/2014)... - Aequus Pharmaceuticals Inc. (the "Company" or "Aequus") ... a brokered private placement offering (the "Brokered Offering") ... Securities Inc. and Clarus Securities Inc. acted as ... syndicate of agents that also included Wolverton Securities ... Concurrently with the Brokered Offering, the Company also ...
(Date:11/18/2014)... FL (PRWEB) November 17, 2014 ... point-of-care diagnostic tests – today announces its third ... and Prevention’s (CDC) Get Smart About Antibiotics Week ... Week is a national campaign designed to highlight ... health departments, and non-profit and for-profit partners to ...
(Date:11/18/2014)... New Brunswick, NJ (PRWEB) November 18, 2014 ... of Data Quality and Transparency Reporting solutions, announced ... has gone live using its Consummate Provider™ solution ... Consummate Provider™ is a Global, SaaS based, Data ... Science organizations and their third party Providers improve ...
Breaking Biology Technology:“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3Alanda Software Completes Successful Implementation of Global Data Quality & Vendor Management Solution for Top Tier Global Biopharmaceutical Company 2
... NEW YORK, Jan. 27, 2011 The Alzheimer,s ... has awarded a grant of $195,000 to ALS ... toxic proteins implicated in Alzheimer,s disease. ... will identify and develop small-molecule brain-penetrant inducers of ...
... SAN CARLOS, Calif. and HOPKINTON, Mass., Jan. 27, ... Sciences, Inc. (Nasdaq: CALP ) today ... automated methods for next generation sequencing sample preparation ... to enable researchers to leverage NuGEN,s Ovation® and ...
... technique for rapidly prototyping nanoscale devices and structures that ... away when done. Hard-tip, soft-spring lithography (HSL) rolls ... high resolution -- and the best of polymer pen ... HSL could be used in the areas of electronics ...
Cached Biology Technology:Alzheimer's Drug Discovery Foundation Funds ALS Biopharma to Develop Small Molecules for Alzheimer's Disease 2NuGEN and Caliper Partner to Eliminate Next-Gen Sequencing Sample Preparation Bottlenecks 2NuGEN and Caliper Partner to Eliminate Next-Gen Sequencing Sample Preparation Bottlenecks 3Making a point 2Making a point 3
(Date:11/4/2014)... 4, 2014   Neurotechnology , a provider ... the latest version of its fingerprint matching algorithm ... MINEX evaluation organized by NIST. The MINEX ... the INCITS 378 fingerprint standard template format. MINEX ... tenders in the United States ...
(Date:11/3/2014)... ANGELES , Nov. 3, 2014  NeuroSigma ... -based life sciences company focused on commercialization ... system for the treatment of neurological and ... of Industrial Property has issued a Notice of ... patent application is co-owned by NeuroSigma and the ...
(Date:11/2/2014)... support of a bold quest to rid the world ... today announced an award of US$156 million to PATH ... building new vaccines that will interrupt the cycle of ... zero" agenda. Such vaccines would ensure that parasite reintroduction ... "immunological bed net." , This approach to developing ...
Breaking Biology News(10 mins):Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 4
... provide a look at the ash and gas clouds being ... NOAA,s GOES-13 satellite to provide a week long look at ... westerly winds carry the debris (ash and smoke) far to ... down the ash before it can go far in the ...
... 2012 Scientists at The Scripps Research Institute have ... the market to treat neuropathic pain and epilepsy, helps ... treatments, gabapentin targets stress systems in the brain that ... 12-week trial of 50 treatment-seeking cannabis users, those who ...
... /PRNewswire-iReach/  -- Global Information Inc. is announces limited time ... important Boston healthcare conferences: Next-Gen Kinase ... rapidly maturing kinase inhibitors field will gather to explore ... Next-Gen Kinase Inhibitors Conference in Cambridge, MA. ...
Cached Biology News:NASA's new satellite movie of 1 week's ash activity from Mexico's Popocatepetl Volcano 2Scripps research scientists find anticonvulsant drug helps marijuana smokers kick the habit 2Scripps research scientists find anticonvulsant drug helps marijuana smokers kick the habit 3Attendees Save Up To $800 on Boston-area Pharmaceutical and Healthcare Conferences, Early Bird Discounts Expiring April 27 2Attendees Save Up To $800 on Boston-area Pharmaceutical and Healthcare Conferences, Early Bird Discounts Expiring April 27 3